The Conversation (0)
Boston Therapeutics Inc (OTCQB:BTHE) announced that it has requested for an Investigational New Drug application meeting with the US FDA to support a proposed indication of the company’s PAZ320 which is designed to lower the elevation of postprandial glucose for patients with Type 2 diabetes.
Boston Therapeutics Inc (OTCQB:BTHE) announced that it has requested for an Investigational New Drug application meeting with the US FDA to support a proposed indication of the company’s PAZ320 which is designed to lower the elevation of postprandial glucose for patients with Type 2 diabetes.
As quoted in the press release:
This IND meeting will be another important milestone in the clinical development program of PAZ320 for the treatment of diabetes,” said David Platt, Ph.D., Chief Executive Officer of Boston Therapeutics. “Our leadership position in complex carbohydrate chemistry enables us to bring new treatment options to a disease that is reaching epidemic proportions. PAZ320 as a new class of anti-diabetes drug may be the key to prevention or managing type 2 diabetes.
Click here to read the full Boston Therapeutics Inc (OTCQB:BTHE) press release.
